

Contents

<i>Introduction</i>	xi
<i>List of icons</i>	xv
<i>Abbreviations</i>	xix
1 The Case: The salutorian who couldn't speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent	1
The Question: What do you do when anxiety fails to respond to multiple SSRIs and cognitive-behavioral therapy (CBT)?	
The Psychopharmacological Dilemma: Whether and when to add adjunctive benzodiazepines remains unclear for many clinicians	
2 The Case: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation	17
The Question: How can clinicians predict side effects associated with SSRIs in children and adolescents?	
The Psychopharmacological Dilemma: Balancing side effects, side-effect management, and efficacy is challenging	
3 The Case: The girl who couldn't sleep: posttraumatic stress disorder (PTSD) in a young girl	35
The Question: When should adjunctive medications be used in pediatric PTSD?	
The Psychopharmacological Dilemma: Randomized clinical trials of first-line medications, such as selective serotonin reuptake inhibitors (SSRIs), in adults with PTSD generally fail to show benefit in children and adolescents with PTSD	
4 The Case: Depressed and still depressed: major depressive disorder (MDD) in an adolescent	49
The Question: When should adjunctive medications be used in adolescents with treatment-resistant MDD?	
The Psychopharmacological Dilemma: There is uncertainty regarding how and when to "change course" in managing treatment-resistant MDD in adolescents, and adjunctive medications may have unique tolerability concerns related to primary pharmacotherapy in this age group	

Contents

- 5 The Case:** A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent 65
The Questions: What medications should be used in an adolescent who develops mania when treated with an SSRI? Does SSRI-related mania represent bipolar disorder?
The Psychopharmacological Dilemma: How to treat patients who are at “high risk” for developing bipolar disorder but are experiencing depressive and/or anxiety symptoms presents a challenge for many clinicians, particularly as SSRIs are the first-line pharmacotherapy for adolescents with depressive and anxiety disorders
- 6 The Case:** Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent 77
The Question: When should medications other than selective serotonin reuptake inhibitors (SSRIs) be used, and how should clomipramine be dosed and monitored in pediatric OCD?
The Psychopharmacological Dilemma: The decision to move beyond SSRIs in treating adolescents with OCD is difficult for many clinicians. In addition, some clinicians experience trepidation about initiating clomipramine and using therapeutic drug-monitoring strategies
- 7 The Case:** Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child 95
The Question: When should nonstimulant medications be used in pediatric patients with ADHD?
The Psychopharmacological Dilemma: When to add nonstimulants to stimulant medications in children with ADHD is unclear for many clinicians. Furthermore, how to choose a nonstimulant, based on the mechanism of action, is a source of uncertainty
- 8 The Case:** From prodrome to psychosis: early-onset schizophrenia 119
The Question: What constitutes an evidence-based work-up for children and adolescents who have prodromal psychotic symptoms or are experiencing a first psychotic episode?
The Psychopharmacological Dilemma: The approach to the young patient with a possible psychotic disorder is unclear for many clinicians, and varies considerably in practice. How specific factors should be considered and what interventions should be used are common questions for clinicians
- 9 The Case:** Too much, too little, or just right? Lithium dosing in an adolescent 137
The Question: How is lithium dosed differently in adolescents compared with adults?

- The Psychopharmacological Dilemma:** Approaches to monitoring and dosing lithium in pediatric patients differ substantially from the strategies used in adults. This confusion often complicates lithium use and monitoring in adolescents, and represents a significant barrier to using lithium
- 10 The Case:** Tic, tic, tic: motor and vocal tics in a boy 155
The Question: What is the role of pharmacotherapy in Tourette syndrome?
The Psychopharmacological Dilemma: Although tics can be common in children and adolescents, choosing among pharmacological approaches to management of Tourette syndrome is complex
- 11 The Case:** How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent 173
The Questions: When should SSRIs be discontinued in adolescents? How should SSRIs be discontinued in adolescents? What are the strategies for managing SSRI-related discontinuation symptoms?
The Psychopharmacological Dilemma: Stopping SSRIs after remission is certainly a goal of treating adolescents with depressive and anxiety disorders, although clinicians vary in their thresholds for discontinuing these medications, and disagree about approaches to discontinuation of SSRIs
- 12 The Case:** The adolescent who doesn't eat: anorexia nervosa in an adolescent 185
The Questions: What is the "medical" workup in a child or adolescent with an eating disorder? When should a child or adolescent with anorexia nervosa be hospitalized? What is the psychopharmacological approach to treating eating disorders and related behaviors in children and adolescents?
The Psychopharmacological Dilemma: Eating disorders can create anxiety for many clinicians as a result of confusion related to the medical workup for these patients, treatment decisions, and special considerations related to using pharmacotherapy in this population
- 13 The Case:** High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent 203
The Questions: How does cannabis affect outcomes in adolescents with depressive disorders? What is the impact of cannabis on selective serotonin reuptake inhibitor (SSRI) pharmacokinetics in adolescents?
The Psychopharmacological Dilemma: Cannabis use is increasingly common in adolescents, yet the pharmacological implications are unclear for many clinicians

Contents

- 14 The Case:** The boy whose bed was always wet: nocturnal enuresis in a child 223
The Question: What is the role of pharmacotherapy in managing nocturnal enuresis in children?
The Psychopharmacological Dilemma: Views on when and how to use pharmacotherapy in children with nocturnal enuresis vary considerably among clinicians
- 15 The Case:** Counting sheep and counting treatment trials: insomnia disorder in an adolescent 233
The Question: What is the evidence-based approach to addressing insomnia in adolescents?
The Psychopharmacological Dilemma: Managing sleep-related problems in adolescents – particularly in those with anxiety and/or depressive disorders – is complicated and requires an understanding of developmental and pharmacological principles
- 16 The Case:** Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD) 259
The Questions: What is the evidence-based workup for a child with ASD? Which SGAs have evidence for specific symptoms in children and adolescents with ASD and how should they be diagnosed? How should tolerability of SGAs be monitored in children and adolescents with ASD?
The Psychopharmacological Dilemma: Managing SGAs in children and adolescents with ASD can be complicated, but awareness of pharmacological/pharmacogenetic principles can help to predict specific tolerability concerns
- 17 The Case:** The “standard treatment” is earning a “D”: treatment-resistant schizophrenia 279
The Question: When and how should clozapine be used in older adolescents with treatment-resistant schizophrenia?
The Psychopharmacological Dilemma: When to use clozapine and how to dose and monitor its use is a source of debate and uncertainty for many clinicians, yet the evidence – largely based on decades of studies in adults – suggests that this agent has response rates substantially higher than those for other second-generation antipsychotics (SGAs) in patients with treatment-resistant schizophrenia
- 18 The Case:** Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent 301

The Questions: How should SSRIs be cross-titrated in adolescents?

What is mechanism-based inhibition, and how does it relate to the pharmacokinetics of some SSRIs in adolescents?

The Psychopharmacological Dilemma: SSRIs are commonly associated with tremendous improvement in adolescents with anxiety and depressive disorders; however, they may be associated with side effects that require medication changes. Cross-titrating SSRIs requires an understanding of both pharmacodynamic and pharmacokinetic principles

Appendices	323
Index of case studies	333
Index of drug names	343